ESMO 2026 at a glance

ESMO AI 2026 will bring attention to developments in AI in oncology, precision oncology and digital health, with a growing focus on the transition from model innovation towards clinical implementation.

This LucidQuest conference preview examines the scientific themes, competitor and industry signals, and emerging technologies that could influence oncology research, clinical adoption and drug development.

📅 Build your schedule around the sessions that matter most.

📥 Download the  ESMO AI 2026_Preview_by_LucidQuest

Key Themes to Watch at ESMO AI 2026

Multimodal Foundation Models

Integration of imaging, pathology, molecular and clinical data could expand AI applications in oncology decision-making.

AI in Pathology: Biomarkers and Precision Oncology

Computational pathology, spatial biology and HER2 scoring will remain central to precision oncology discussions.

Real-World Data and Clinical AI Scalability

EHR integration, data harmonisation and interoperability may determine clinical AI scalability.

Digital Oncology and Patient Monitoring

Wearables, ePROs and virtual follow-up could strengthen supportive care and patient monitoring.

Competitor and Industry Signals at ESMO AI 2026

AstraZeneca: AI-Enabled HER2 Scoring

Evaluation of seven AI solutions for HER2 scoring, including HER2-low and HER2-ultralow assessment.

Flatiron Health: Digital Twins and Predictive Modelling

Digital twins and predictive modelling could inform oncology drug-development decisions.

Johnson & Johnson: Digital Pathology and Clinical Trials

Digital pathology, patient identification and EHR-to-EDC technology will connect precision medicine with clinical trials.

MSD and Fraunhofer IIS: AI-Powered Spatial Biomarkers

AI-powered spatial biomarkers and MIKAIA will highlight computational pathology applications.

Agentic AI in Oncology Workflows

Octozi and other innovators will examine AI agents for trial-data cleaning, medical review and oncology workflows.

Responsible AI and Clinical Adoption

Explainability, validation and human oversight will shape discussions around clinical adoption.

Emerging AI Platforms in Oncology

Nexomic, StratifAI and TwinEdge Bioscience will explore multiomic AI, multimodal diagnostics and digital patient avatars.

What We Are Watching After ESMO AI 2026

  • Whether multimodal foundation models demonstrate clinical value beyond research benchmarks.

  • Whether autonomous AI and pathology tools show sufficient reliability and validation for routine use.

  • Whether AI-assisted recruitment, digital twins and real-world data translate into more efficient oncology development.

Download the ESMO AI 2026 Preview Report

Download our ESMO AI 2026 preview report for a closer look at emerging technologies, competitive signals and strategic implications for AI in oncology.

📅 Build your schedule around the sessions that matter most.

📥 Download the  ESMO AI 2026_Preview_by_LucidQuest

Contact us for end-to-end conference coverage.

Privacy Preference Center